Protalix BioTherapeutics has higher revenue and earnings than Humacyte. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the ...
In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a ...
Humacyte's innovative ATEV technology shows promise but faces delays in FDA approval, initially expected in Aug, causing financial strain and uncertainty about its market potential. Despite strong ...
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of ...
Financial giants have made a conspicuous bearish move on Humacyte. Our analysis of options history for Humacyte (NASDAQ:HUMA) revealed 9 unusual trades. Delving into the details, we found 11% of ...
DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered ...
https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-price-target-lowered-to-460-from-550-at-truist Benchmark analyst Bruce Jackson raised the firm’s price ...
San Francisco, California--(Newsfile Corp. - December 18, 2024) - Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles ...
LOS ANGELES, CA / ACCESSWIRE / January 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback